Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Aripiprazole LAI in Schizophrenia or Bipolar I
NCT03854409Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aripiprazole in schizophrenia and bipolar I disorder (7 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Maximum Observed Plasma Concentration, Plasma Concentration at 28 Days Postdose and 7 more. Started Jan 2019; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT03854409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854409.